康芝药业
(300086)
| 流通市值：20.17亿 | | | 总市值：20.84亿 |
| 流通股本：4.36亿 | | | 总股本：4.50亿 |
| 报告期 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 104,642,937.86 | 171,581,262.17 | 179,524,082.61 | 269,812,342.27 |
| 应收票据及应收账款 | 45,982,373.91 | 60,393,472.79 | 56,503,756.61 | 73,139,733.2 |
| 其中：应收票据 | 318,634.8 | 8,780,068.2 | 6,409,739.55 | 2,008,886.6 |
| 应收账款 | 45,663,739.11 | 51,613,404.59 | 50,094,017.06 | 71,130,846.6 |
| 预付款项 | 37,394,621.26 | 39,881,274.77 | 38,885,057.61 | 88,700,391.29 |
| 其他应收款合计 | 65,897,625.55 | 57,306,431.65 | 67,808,019.04 | 67,635,007.13 |
| 存货 | 264,127,007.92 | 248,073,560.05 | 222,691,380.6 | 170,403,668.09 |
| 其他流动资产 | 7,723,063.36 | 2,669,865.14 | 3,111,048.39 | 768,883.39 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 525,767,629.86 | 579,905,866.57 | 568,523,344.86 | 670,460,025.37 |
| 非流动资产: | | | | |
| 其他权益工具投资 | 5,946,251.81 | 5,946,251.81 | 5,946,251.81 | 5,946,251.81 |
| 投资性房地产 | 237,607,487.29 | 237,607,487.29 | 237,607,487.29 | 237,607,487.29 |
| 固定资产 | 856,787,759.89 | 863,417,453.55 | 877,816,278.5 | 890,943,057.14 |
| 在建工程 | 125,131,029.42 | 89,444,611.46 | 59,699,922.17 | 59,590,586 |
| 无形资产 | 161,077,665.91 | 163,059,227.97 | 165,255,657.2 | 167,552,081.31 |
| 开发支出 | 38,139,470.7 | 38,139,470.7 | 38,139,470.7 | 37,347,111.74 |
| 商誉 | 18,891,963.66 | 18,891,963.66 | 18,891,963.66 | 18,891,963.66 |
| 长期待摊费用 | 35,645,948.88 | 37,559,120.27 | 38,794,820.04 | 37,859,654.89 |
| 递延所得税资产 | 43,782,381.92 | 49,199,789.92 | 47,636,924.18 | 47,904,702.04 |
| 其他非流动资产 | 38,884,484.29 | 61,931,931.9 | 90,725,931.4 | 114,368,840.15 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 1,561,894,443.77 | 1,565,197,308.53 | 1,580,514,706.95 | 1,618,011,736.03 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 2,087,662,073.63 | 2,145,103,175.1 | 2,149,038,051.81 | 2,288,471,761.4 |
| 流动负债: | | | | |
| 短期借款 | 84,000,000 | 105,000,000 | 105,620,000 | 133,217,958.15 |
| 应付票据及应付账款 | 99,848,184.32 | 104,829,450.2 | 58,491,089.59 | 57,401,453.35 |
| 其中：应付票据 | 40,000,000 | 40,000,000 | - | - |
| 应付账款 | 59,848,184.32 | 64,829,450.2 | 58,491,089.59 | 57,401,453.35 |
| 预收款项 | 21,148 | 26,730 | 8,310 | 11,676 |
| 合同负债 | 13,993,848.84 | 17,846,004.71 | 23,867,150.93 | 95,657,672.2 |
| 应付职工薪酬 | 8,781,887.04 | 8,576,739.92 | 10,624,191.23 | 11,070,094.2 |
| 应交税费 | 16,705,192.99 | 14,946,693.28 | 13,728,436.84 | 24,992,409.21 |
| 其他应付款合计 | 62,308,083.87 | 60,437,401.71 | 69,899,506.6 | 71,361,939.81 |
| 其中:应付利息 | - | - | 640,688 | - |
| 一年内到期的非流动负债 | 69,710,000 | 69,710,000 | 86,510,800.91 | 107,054,394.1 |
| 其他流动负债 | 1,812,681.22 | 2,312,522.88 | 3,100,898.41 | 3,742,957.33 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 357,181,026.28 | 383,685,542.7 | 371,850,384.51 | 504,510,554.35 |
| 非流动负债: | | | | |
| 长期借款 | 305,140,688 | 306,640,688 | 322,329,000 | 342,845,778.3 |
| 递延收益 | 48,866,313.06 | 49,574,093.67 | 50,288,257.28 | 51,002,420.89 |
| 递延所得税负债 | 35,151,895.09 | 34,969,395.08 | 34,786,895.08 | 34,604,395.08 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 389,158,896.15 | 391,184,176.75 | 407,404,152.36 | 428,452,594.27 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 746,339,922.43 | 774,869,719.45 | 779,254,536.87 | 932,963,148.62 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 450,000,000 | 450,000,000 | 450,000,000 | 450,000,000 |
| 资本公积 | 827,726,146.8 | 818,960,496.79 | 818,960,496.79 | 818,960,496.79 |
| 其他综合收益 | 52,469,738.35 | 52,469,738.35 | 52,469,738.35 | 52,469,738.35 |
| 盈余公积 | 52,826,487.28 | 52,826,487.28 | 52,826,487.28 | 52,826,487.28 |
| 未分配利润 | -78,526,084 | -41,762,248.32 | -42,658,943.33 | -58,073,616.6 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 1,304,496,288.43 | 1,332,494,474.1 | 1,331,597,779.09 | 1,316,183,105.82 |
| 少数股东权益 | 36,825,862.77 | 37,738,981.55 | 38,185,735.85 | 39,325,506.96 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 1,341,322,151.2 | 1,370,233,455.65 | 1,369,783,514.94 | 1,355,508,612.78 |
| 负债和股东权益合计 | 2,087,662,073.63 | 2,145,103,175.1 | 2,149,038,051.81 | 2,288,471,761.4 |
| 公告日期 | 2023-10-27 | 2023-08-29 | 2023-04-28 | 2023-04-24 |
| 审计意见(境内) | | | | 标准无保留意见 |